Introduction
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world [1] and with 42.2 and 36.1 new cases per 100,000 people per year for men and women, respectively, Norway is among the European countries with the highest incidence of CRC [2] . Most cases of CRC are sporadic and are thought to be driven by genetic mutations, epigenetic changes and chronic inflammation, as well as diet and lifestyle behaviors [3] . Colorectal cancer develops partly through adenomas and screening by colonoscopy is an effective, although costly, way to prevent CRC by identifying and removing pre-cancerous adenomas. In line with this, patients diagnosed with localized disease have an 80-90% five-year survival rate while the survival rate drops to under 10% for carcinomas with distant metastasis [4] .
Surgery is the standard treatment for CRC that has not spread to distant sites, but patients with advanced and aggressive disease need adjuvant therapies, primarily involving chemoand radiation therapy which may considerably improve prognosis.
The host immune system is capable of mounting immune responses to the tumor cells, mainly through tumor infiltrating T lymphocytes and natural killer cells [5] . However, immune surveillance and activation are frequently ineffective in preventing or controlling tumor growth, and colorectal cancers have been shown to induce immune suppression linked to poorer clinical outcome [6] . Several mechanisms for immune suppression have been described, but the aberrant expression of cyclooxygenase-2 (COX-2) and its role in the production of prostaglandin E 2 (PGE 2 ) has a strong association with the development and maintenance of CRC [7] . Cyclooxygenase-2 has been found to be overexpressed in 40% of colorectal adenomas [8] and in up to 90% of carcinomas [9] . Furthermore, we have previously revealed that CRC patients have elevated levels of circulating PGE 2 in their blood [10] . The crucial role of COX-2 and PGE 2 in CRC carcinogenesis is demonstrated by randomized trials proving regular pharmacological inhibition of the COX-enzymes with nonsteroidal anti-inflammatory drugs (NSAIDs) to be effective in reducing both the incidence and progression of intestinal tumors in CRC patients [11] . However, long-term use has been associated with side effects in the gastrointestinal tract and cardiovascular system which has dampened their use as chemopreventive agents. Additional modes of therapy and chemoprevention of CRC that are both effective and tolerable remain to be developed, and the PGE 2 signaling pathway is a potential target which necessitates insight into the immunomodulatory role of PGE 2 in CRC pathology.
Cyclic adenosine monophosphate (cAMP) is the main intracellular second messenger of PGE 2 and increased production of cAMP is known to inhibit TCR signaling through the protein kinase A (PKA) type I-CSK (COOH-terminal Src kinase)-LCK (lymphocyte-specific protein tyrosine kinase) signaling cascade [12] . The TCR complex lacks intrinsic enzymatic activity, but upon triggering of T cells, the tyrosine kinase LCK rapidly becomes activated and phosphorylates tyrosine residues within specialized motifs (immunoreceptor tyrosine based activation motifs; ITAMs) in the cytoplasmic tail of the signal transduction unit of the TCR/CD3 complex, the CD3 chains. Upon T-cell activation, PKA type I redistributes to and co-localizes with the TCR/CD3 complex [13] and phosphorylates its TCR proximal substrate CSK at serine 364, resulting in increased CSK activity [12] . CSK subsequently provides negative control of LCK by phosphorylating the inhibitory tyrosine 505 [14] . As a result, The present study was designed to find out whether the levels of circulating PGE 2 from the tumor and immune system in patients with CRC affect stimulation responses of peripheral T cells. Blood was drawn from patients not undergoing adjuvant therapy or receiving medication inflicting with prostaglandin synthesis and from healthy blood donors.
We measured PGE 2 levels and profiled signaling cascades in various T cell subsets after triggering T-cell-, prostaglandin-and interleukin-2 receptors in a phospho-specific flow cytometric setup.
Materials and Methods

Patient material
The study was approved by the Regional Committee for Medical Research Ethics, for SouthEastern Norway and conducted in compliance with the Declaration of Helsinki. Patients with colorectal cancer at the Department of Gastrointestinal Surgery, Oslo University Hospital, were enrolled in the study after obtaining written informed consent. 11 patients were enrolled in the study and ten of the patients were included in the final analysis (six women and four men; average age 67.2 years; range 
Statistical analysis
Data were analyzed using SigmaPlot 11.0 (Systat Software Inc., San Jose, CA, USA).
Median values were compared with Mann-Whitney Rank Sum test and with Student T-test for pair-wise comparisons when normally distributed (Fig 3B) . p < 0.05 was considered significant.
Results
Patient characteristics
Eleven CRC patients were enrolled in the study, but one patient was excluded when the histopathological diagnosis was B cell lymphoma of the gut rather than CRC. Clinical characteristics of patients are presented in Table 1 . TNM staging (T; tumor invasion, N; lymphatic node, M; metastasis, combined with numbers from 0 to 4 indicating increasing severity) according to the American Joint Committee on Cancer showed that nine out of ten patients were staged T3 or T4, meaning that the tumor had grown into the outermost layers of the colon or rectum or into organ structures. Half of the patients had spreading to regional lymph nodes whereas only one patient had distant metastasis. No correlation between PGE 2 levels and number of positive lymph nodes or with levels of the tumor marker carcinoembryonic antigen (CEA) could be observed.
Plasma concentrations of PGE 2 and phenotypic characterization of T cell subsets
Examining plasma concentrations of PGE 2 it was clear that the patient group was not homogenous, but could be stratified into two groups, one with significantly higher plasma concentrations of PGE 2 (n=6; > 1000 pg/ml) than the other (n=4; < 1000 pg/ml) (Fig. 1A) . Tcell signaling was therefore separately analyzed for each of these groups. Furthermore, PGE 2 levels in the patient group with low levels of PGE 2 were not significantly different from those of healthy blood donors that were included as controls (Fig. 1A) .
Activation of T lymphocytes occurs in lymphoid tissue and generates functionally diverse subsets of effector T cells that can be phenotypically distinguished by the expression of CD45RO. All patient and control samples were therefore subjected to flow cytometric analysis of their surface expression of CD4 and CD45RO for a more detailed subset analysis of CD4 and CD8 (identified as CD4 − ) and CD45RO − naïve T cells and CD45RO + effector/memory T cells (Fig. 1B) . However, stratification on PGE 2 levels did not reveal any differences in distribution of specific T cell subsets (Fig. 1C ).
Signal network mapping in CRC patient samples
Earlier studies from our group have mapped PGE 2 pathways in lymphoid cells from healthy . In parallel, the same protocol was applied to blood samples from healthy blood donors. Not all monitored phosphorylation parameters responded to the various treatments. Consequently, non-informative readouts were excluded from the rest of the analysis. T-cell signaling analysis from the CRC patient group as a whole versus blood donors did not reveal any significant signaling differences (data not shown). We therefore next stratified the group on PGE 2 plasma concentrations, as accounted for in the previous section, into separate groups of samples from patients with low and high levels of PGE 2 . This enabled identification of PGE 2 sensitive signaling nodes in T lymphocytes from CRC patients.
Plasma levels of PGE 2 affect proximal T cell receptor signaling events
We found phosphorylation of CD3ζ after one minute of TCR/CD28 co-stimulation to be significantly reduced in the CRC patient samples with elevated plasma levels of PGE 2 when compared to CRC patient samples with lower levels of PGE 2 and to samples obtained from healthy blood donors (Fig. 3A) . The same tendency was observed in all T cell subsets investigated, although not significant for all comparisons. To test whether the cells were exhausted with respect to PGE 2 responsiveness by endogenous stimuli, we also pre-incubated the cells with 10 µM exogenous PGE 2 prior to one minute of anti-CD3/CD28 co-stimulation.
The phosphorylation of CD3ζ was then compared pairwise to responses in the samples from the same individual without addition of PGE 2 prior to TCR/CD28 co-stimulation. A significant reduction in phosphorylation of CD3ζ was found in all samples (Fig. 3B) .
A Phosphorylation of SLP76 clearly mirrored the results obtained for CD3ζ (Fig. 3C) where CRC patient samples measured to have elevated PGE 2 levels revealed reduced responses in SLP76 phosphorylation. Basal phosphorylation of both CD3ζ and SLP76 proteins were negligible in all subsets and for all groups of study participants (data not shown).
1.3.5
The PKA signaling node of CRC patients with elevated plasma levels of PGE 2 was not affected Activation of PKA by cAMP results in phosphorylation of nearby target substrates on serine or threonine residues presented in a preferred amino acid sequence context of argininearginine-X-serine/threonine (where X denotes any amino acid) [24] . The anti-phospho PKA substrate antibody recognizes phosphorylated PKA substrates and was used to assess PKA activation in response to PGE 2 treatment (Fig. 4A) . We have previously reported maximum response for phosphorylation of PKA substrates to occur ten minutes after exposure to 10 µM PGE 2 [20] and this stimulation condition was therefore chosen for our study samples.
However, we did not observe blunted responses in the PKA signaling node in CRC patient samples with higher PGE 2 plasma levels. The levels of phosphorylation of direct targets of PKA such as VASP (vasodilator-stimulated phospho-protein) and GSK (glycogen synthase kinase) 3α ( Fig. 4C and 4E , respectively) were neither affected. Variability among donor samples complicated conclusive readouts for the phospho-epitopes in the PKA signaling node.
When comparing basal phosphorylation levels of proteins in the PKA signaling node, the CD4 − CD45RO + cells generally exhibited higher basal levels of activation than the other subsets (Fig. 4B, 4D and 4F ). This observation has previously been reported from our group and was found to correlate with suppressed proximal TCR signaling [20] , thus indicating that the PKA activity might prevent inappropriate activation of effector/memory cells.
Of note, stimulation with PGE 2 alone did not directly affect the phosphorylation status of TCR proximal signaling molecules investigated in the present study (see Fig. 2B ).
1.3.6 Long-term exposure to PGE 2 inhibits IL-2-specific phosphorylation of
STAT5
Signal disturbance caused by PGE 2 on the IL-2 receptor pathway was tracked by IL-2-induced phosphorylation of the transcription factor STAT5 (signal transducer and activator of transcription 5). T cells isolated from patients with increased levels of PGE 2 responded more poorly to IL-2 treatment than T cells from control groups (Fig. 5A) . Furthermore, we also analyzed evoked phospho-STAT5 responses after adding PGE 2 on top of IL-2 stimulation, but found no apparent changes (data not shown). Another observation was the higher basal level of STAT5 phosphorylation in the CD4 − population (Fig. 5B ).
Discussion
Prostaglandin E 2 is one of the most important biologically active prostaglandins found throughout the gastrointestinal tract [26] and promotes cell proliferation, angiogenesis, migration, tumor invasion and inhibition of apoptosis [27] . Consequently, PGE 2 also influences on the carcinogenesis and progression of colorectal cancer. Our earlier studies revealed that elevated circulating levels of PGE 2 are found in a proportion of patients with both primary and metastatic CRC [10, 28] and that PGE 2 levels take months to return to normal after surgery. The short half-life of PGE 2 indicates that COX-2 positive tumors are not the only source of PGE 2 , a significant part of the PGE 2 production probably comes from inflammatory cells. Furthermore, we demonstrated that PGE 2 -mediated suppression of antitumor immune responses takes place both in primary and metastatic cancer and that the level of such suppression predicts clinical outcome [10, 28] . With this background, it was of interest to assess whether elevated PGE 2 levels correlated with perturbed signaling downstream of the TCR and IL-2 receptor in peripheral T cells from CRC patients. Our present study supports the notion that PGE 2 builds up an immunosuppressive network, also affecting the host at systemic levels.
Six out of ten CRC patient samples exhibited elevated PGE 2 plasma levels (Fig. 1A) .
Dysregulated expression of COX-2 is considered the major determinant of PGE 2 levels in CRC, but specific prostaglandin E synthases have like COX-2 been found to be up-regulated in colorectal tumors [29] . Enzymes catalyzing degradation of prostaglandins are less evaluated in relationship to tumor progression, but loss of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) has been reported in colorectal tumors [30] . A role for differential expression of the four PGE 2 receptors (EP1-4) during human colorectal tumorigenesis has also been implied. Colorectal cancer cells and their neighbor cells have been shown to have augmented expression of receptors EP2 [31] and EP4 [32] that stimulate cAMP production upon activation, whereas the EP3 receptor expression, known to inhibit cAMP production upon activation, is often lowered in target cells [33] . Collectively, these data reflect that the impact of PGE 2 in CRC pathogenesis is caused by an imbalance in PGE 2 synthesis and turnover and in the pattern of receptor expression.
The most profound signaling differences in the present study were found in the phosphorylation of CD3ζ after one minute of TCR/CD28 co-stimulation, elevated plasma levels of PGE 2 were associated with reduced phosphorylation of CD3ζ (Fig. 3A) .
Prostaglandin E 2 signals mainly in a cAMP-dependent fashion in T cells and inhibits TCR signaling through the PKA type I-CSK-LCK pathway [12, 14] . Since phosphorylation of CD3ζ in all samples were responsive to the addition of exogenous PGE 2 , independent of the endogenous levels of PGE 2 , the inhibitory pathway did not seem to be fully desensitized in any population. Immune dysfunction in T cells from CRC patients and tumor-bearing mice have otherwise previously been suggested to be caused by loss of key signaling molecules associated with TCR, such as CD3ζ and LCK [34] [35] [36] .
Prostaglandin E 2 acts as a second messenger related to G-protein coupled receptors and in response to repeated or long-lasting stimuli, second messenger signals are often dampened due to negative feedback loops or desensitization mechanisms [37] . Downregulation of EP receptors or PGE 2 signaling elements after prolonged exposure of PGE 2 could therefore be a plausible explanation for the non-conclusive readouts in PGE 2 signaling targets (Fig. 4) .
Interleukin-2 is a potent T cell mitogenic stimulus and has been exploited as a means to boost immune responses to cancer, but has shown no clinical benefit in CRC [38] . Our study is in agreement with accumulated evidence from several groups indicating that increased PGE 2 levels exert negative control on IL-2 stimulated responses, assessed by IL-2-induced activation of STAT5 (Fig. 5A ) [15] [16] [17] [18] 39] . The IL-2 receptor functions as a heterotrimer and the high affinity IL-2R contains all three subunits, IL-2Rα, β and the common γc. Expression and dimerization of the β and γc chains alone are sufficient to mediate IL-2 dependent signaling [40] . We found IL-2 to induce higher phosphorylation responses of phospho-STAT5 in the memory compartment. This can be explained by their constitutive expression of both IL2-Rβ and γc, contrary to naïve cells which require activation-induced up-regulation of the β chain [41] .
In conclusion, despite a small sample size we found that proximal T-cell phosphorylation cascades were blunted in CRC patient samples with elevated PGE 2 levels.
Our findings thereby add to previous results on PGE 2 as a negative regulator of T-cell signaling and a key mediator of immunopathology in cancer. However, PGE 2 -regulated networks are likely to act in concert with other important signaling pathways not investigated in this study that become dysregulated in CRC. Furthermore, we confirmed phospho-specific flow cytometry to be a valuable tool for revealing specific signaling signatures of T-cell activation that could reflect regulation of anti-tumor immunity in CRC.
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